Uwell Biopharma, Inc. (TPEX:7902)
Taiwan · Delayed Price · Currency is TWD 35.90
-0.05 (-0.14%)
At close: Sep 7, 2026
Uwell Biopharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.04 | 0.04 | 0.45 | - | - | - | |
Revenue Growth | -92.22% | -92.22% | - | - | - | - |
Cost of Revenue | 0.01 | 0.01 | 0.15 | - | - | - |
Gross Profit | 0.03 | 0.03 | 0.3 | - | - | - |
Selling, General & Admin | 23.62 | 14.66 | 11.09 | 11.47 | 11.52 | 14.19 |
Research & Development | 52.16 | 53.75 | 32.63 | 37.18 | 38.51 | 35.45 |
Operating Expenses | 75.78 | 68.42 | 43.72 | 48.64 | 50.03 | 49.64 |
Operating Income | -75.76 | -68.39 | -43.42 | -48.64 | -50.03 | -49.64 |
Interest Expense | -0.2 | -0.15 | -0.21 | -0.22 | -0.28 | -0.42 |
Interest & Investment Income | 4.3 | 2.32 | 0.83 | 0.62 | 0.26 | 0.05 |
Other Non Operating Income (Expenses) | 0.05 | 0.02 | 1.92 | 3.08 | 8.58 | 0.01 |
EBT Excluding Unusual Items | -71.61 | -66.2 | -40.87 | -45.17 | -41.47 | -49.99 |
Pretax Income | -71.61 | -66.2 | -40.87 | -45.17 | -41.47 | -49.99 |
Net Income | -71.61 | -66.2 | -40.87 | -45.17 | -41.47 | -49.99 |
Net Income to Common | -71.61 | -66.2 | -40.87 | -45.17 | -41.47 | -49.99 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 195 | 153 | 117 | 89 | 57 | 24 |
Shares Outstanding (Diluted) | 195 | 153 | 117 | 89 | 57 | 24 |
Shares Change | 66.46% | 30.97% | 31.62% | 55.95% | 141.86% | 11.16% |
EPS (Basic) | -0.37 | -0.43 | -0.35 | -0.51 | -0.73 | -2.12 |
EPS (Diluted) | -0.37 | -0.43 | -0.35 | -0.51 | -0.73 | -2.12 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -64.62 | -54.36 | -32.38 | -42.64 | -35.86 | -43.65 |
Free Cash Flow Per Share | -0.33 | -0.35 | -0.28 | -0.48 | -0.63 | -1.85 |
Gross Margin | 80.00% | 80.00% | 66.89% | - | - | - |
Operating Margin | -216445.71% | -195391.43% | -9648.00% | - | - | - |
Profit Margin | -204605.71% | -189137.14% | -9082.67% | - | - | - |
Free Cash Flow Margin | -184634.29% | -155300.00% | -7196.22% | - | - | - |
EBITDA | -72.23 | -65.14 | -40.32 | -45.53 | -47.15 | -47.57 |
D&A For EBITDA | 3.52 | 3.24 | 3.1 | 3.12 | 2.88 | 2.07 |
EBIT | -75.76 | -68.39 | -43.42 | -48.64 | -50.03 | -49.64 |